En studie för behandling av paroxysmalt förmaksflimmer (PAF) med OMNYPULSE-katetern och TRUPULSE-generatorn (Omny-IRE)
Säkerhet och effektivitetsutvärdering av OMNYPULSE-katetern med TRUPULSE-generatorn för behandling av paroxysmalt förmaksflimmer (PAF)
The purpose of this study is to demonstrate safety and effectiveness of the ablation system (OMNYPULSE Bi-directional catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Aalst, Belgien, 9300
- AZORG campus Aalst Moorselbaan
-
Bruges, Belgien, 8000
- AZ Sint-Jan
-
Genk, Belgien, 3600
- Ziekenhuis Oost-Limburg
-
Hasselt, Belgien, 3500
- Jessa Ziekenhuis - Campus Virga Jesse
-
-
-
-
-
Acquaviva delle Fonti, Italien, 70021
- Generale Regionale F. Miulli
-
-
-
-
Quebec
-
Montreal, Quebec, Kanada, H3G 1A4
- McGill University Health Centre
-
Montreal, Quebec, Kanada, H1T 1C8
- Montreal Heart Institute
-
-
-
-
-
Split, Kroatien, 21000
- KBC Split
-
-
-
-
-
Vilnius, Litauen, 08661
- Vilnius University Hospital Santariskiu Klinikos
-
-
-
-
-
Maastricht, Nederländerna, 6229 HX
- Maastricht UMC
-
-
-
-
-
Prague, Tjeckien, 150 30 District 5
- Nemocnice na Homolce
-
Prague, Tjeckien, 140 21
- IKEM
-
-
-
-
-
Frankfurt a.M., Tyskland, 60431
- MVZ CCB Frankfurt und Main Taunus GbR
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Diagnosed with Symptomatic paroxysmal atrial fibrillation (PAF) defined as as atrial fibrillation (AF) that terminates spontaneously or with intervention within 7 days of onset. This PAF is considered to be symptomatic if symptoms related to AF are experienced by the participant
- Selected for AF ablation procedure by pulmonary vein isolation (PVI)
- Willing and capable of providing consent
- Able and willing to comply with all pre-, post- and follow-up testing and requirements
Exclusion Criteria:
- Previously known AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause (example, documented obstructive sleep apnea, acute alcohol toxicity, morbid obesity [body mass index greater than {>} 40 kilograms per meter square {kg/m^2}]), renal insufficiency (with an estimated creatinine clearance less than (<) 30 milliliters per minute per 1.73 meter square [mL/min/1.73 m^2])
- Previous left atrium (LA) ablation or surgery
- Participants known to require ablation outside the PV region (example, atrioventricular reentrant tachycardia, atrioventricular nodal re-entry tachycardia, atrial tachycardia, ventricular tachycardia and Wolff-Parkinson-White)
- Previously diagnosed with persistent AF (> 7 days in duration)
- Severe dilatation of the left atrium (LA) (left anterior descending artery [LAD] >50 millimeter [mm] antero-posterior diameter in case of transthoracic echocardiography [TTE])
- Presence of LA thrombus
- Severely compromised left ventricular ejection fraction (left ventricular ejection fraction [LVEF] <40 percentage [%])
- Uncontrolled heart failure or New York Heart Association (NYHA) Class III or IV
- History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran)
- History of a documented thromboembolic event (including transient ischemic attack [TIA]) within the past 6 months
- Previous percutaneous coronary intervention (PCI) / myocardial infarction (MI) within the past 2 months
- Previous coronary artery bypass grafting (CABG) in conjunction with valvular surgery, cardiac surgery (example, ventriculotomy, atriotomy) or valvular cardiac (surgical or percutaneous) procedure
- Unstable angina pectoris within the past 6 months
- Anticipated cardiac transplantation, cardiac surgery, or other major surgery within the next 12 months
- Significant pulmonary disease (example, restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms
- Known significant pulmonary vein (PV) anomaly that in the opinion of the investigator would preclude enrollment in this study
- Prior diagnosis of pulmonary vein stenosis
- Pre-existing hemi diaphragmatic paralysis
- Acute illness, active systemic infection, or sepsis
- Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation
- Severe mitral regurgitation
- Presence of implanted pacemaker or implantable cardioverter-defibrillator (ICD) or other implanted metal cardiac device that may interfere with the pulsed electric field energy
- Presence of a condition that precludes vascular access (such as Inferior Vena Cava [IVC] filter)
- Significant congenital anomaly or a medical problem that in the opinion of the investigator would preclude enrollment in this study
- Categorized as vulnerable population and requires special treatment with respect to safeguards of well-being
- Current enrollment in an investigational study evaluating another device or drug
- Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of child-bearing age and plan on becoming pregnant during the course of the clinical investigation
- Life expectancy less than 12 months
- Presenting contra-indications for the devices used in the study, as indicated in the respective Instructions For Use (IFU)
- Known contraindication for magnetic resonance imaging (MRI) such as use of contrast agents due to advanced renal disease, claustrophobia etcetra. (at principle investigator [PI] discretion)
- Presence of iron-containing metal fragments in the body
- Known unresolved pre-existing neurological deficit
- Known uncontrolled significant gastroesophageal reflux disease (GERD)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: OMNYPULSE Bi-Directional Catheter with TRUPULSE Generator
Participants with symptomatic paroxysmal atrial fibrillation (PAF) will undergo the ablation procedure with OMNYPULSE bi-directional catheter used in combination with the TRUPULSE generator for pulmonary vein isolation (PVI). |
Participants will undergo catheter ablation with the PF ablation system consisting of the TRUPULSE generator (delivers PF energy through the study catheter) and the OMNYPULSE bi-directional catheter (indicated for use in catheter-based cardiac electrophysiological mapping [stimulating and recording] and, when used with a Generator, for cardiac ablation). |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of Participants With Primary Adverse Events (PAEs)
Tidsram: 90 days post catheter insertion on Day 0
|
Percentage of participants with PAEs was reported. PAEs (within seven [7] days of the index ablation procedure) included the following adverse events atrio-esophageal fistula, pulmonary vein stenosis, device or procedure related death, (up to 90 days post-procedure), phrenic nerve paralysis (permanent), cardiac tamponade/perforation (up to 30 days post-procedure), stroke/cerebrovascular accident (CVA), major vascular access complication, major bleeding, thromboembolism, myocardial infarction, transient ischemic attack (TIA), pericarditis, heart block, pulmonary edema (respiratory insufficiency), and vagal nerve injury/gastroparesis. |
90 days post catheter insertion on Day 0
|
|
Percentage of Participants With Acute Effectiveness Success
Tidsram: Immediately post-procedure on Day 0 (post catheter insertion)
|
Percentage of participants with acute effectiveness success were reported. Procedural success was defined as electrical isolation of clinically relevant targeted pulmonary veins (PV; confirmed by entrance block) after adenosine/isoproterenol challenge at the end of the index ablation procedure. |
Immediately post-procedure on Day 0 (post catheter insertion)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of Participants With Freedom From Combined Documented (Symptomatic and Asymptomatic) Atrial Arrhythmia Episodes and Acute Procedural Failure
Tidsram: From Day 0 to Day 365 post catheter insertion on Day 0
|
Percentage of participants with freedom from combined documented (symptomatic and asymptomatic) atrial arrhythmia episodes and acute procedural failure were reported. Effectiveness success was defined as freedom from documented (symptomatic and asymptomatic) atrial arrhythmia (atrial fibrillation, atrial tachycardia or atrial flutter [AFL] of unknown origin [all AFL except those Cavotricuspid Isthmus (CTI) dependent AFL as confirmed by 12-lead electrocardiogram or entrainment maneuvers in an EP study]) episodes based on electrocardiographic data (greater than or equal to [>=] 30 seconds on arrhythmia monitoring device) during the effectiveness evaluation period (Day 91 to Day 365) on or off antiarrhythmic therapy. Acute procedural failure: failure to achieve entrance block with the study device in any of the clinically relevant targeted pulmonary veins (PVs). Kaplan-Meier (KM) estimate was used. |
From Day 0 to Day 365 post catheter insertion on Day 0
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Biosense Webster, Inc., a division of Johnson & Johnson Clinical Trial, Biosense Webster, Inc., a division of Johnson & Johnson
Publikationer och användbara länkar
Allmänna publikationer
- Duytschaever M, Grimaldi M, De Potter T, Verma A, Macle L, Kautzner J, Linz D, Anic A, Van Herendael H, Rackauskas G, Neuzil P, Chun J, Schmidt B, Knecht S, Almorad A, Berte B, Reddy VY, Vijgen J. PVI With CF-Sensing Large-Tip Focal PFA Catheter With 3D Mapping for Paroxysmal AF: Omny-IRE 3-Month Results. JACC Clin Electrophysiol. 2025 Aug;11(8):1769-1782. doi: 10.1016/j.jacep.2025.04.008. Epub 2025 Apr 25.
- Duytschaever M, Vijgen J, Neuzil P, Grimaldi M, Verma A, De Potter T, Macle L, Kautzner J, Linz D, Anic A, Chun J, Van Herendael H, Almorad A, Berte B, Bhardwaj R, Reichlin T, Mansour M, Schmidt B, Knecht S, Reddy VY, Rackauskas G. Pulmonary vein isolation with a contact force-sensing, large-tip focal pulsed field ablation catheter with 3D mapping for paroxysmal atrial fibrillation: Omny-IRE 12-month results. Heart Rhythm. 2026 Oct 22:S1547-5271(26)02869-9. doi: 10.1016/j.hrthm.2026.10.008. Online ahead of print.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- BWI202201
- BWI202201 (Annan identifierare: Biosense Webster, Inc.)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .